Histologic Healing in Crohn's Disease, 2018 - Focus on KOL Perspectives Featuring Gilead & Celgene

| Source: Research and Markets Research and Markets

Dublin, Feb. 21, 2019 (GLOBE NEWSWIRE) -- The "KOL Perspectives: Histologic Healing in Crohn's disease" drug pipelines has been added to ResearchAndMarkets.com's offering.

This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn's disease.

Questions topics

  • Use of histological assessment in clinical trials and practice in Crohn's disease
  • Extrapolation of UC histology to UC
  • Barriers to adoption of histology assessment in Crohn's disease
  • Impact of histological data in therapy choice in Crohn's diseaseViews on use of Geboes as an endpoint in Crohn's disease
  • Views on Phase II sub-analysis data for filgotinib

Key Highlights

  • Majority of KOLs state that histologic healing is not used to assess Crohn's disease patients in clinical practice
  • Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal
  • Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs

  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018

KOL data is analyzed to produce

  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts

Reasons to Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn's disease
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Key Topics Covered:

  1. Executive Summary
  2. Background
  3. Research Panel Composition
  4. Results & Implications
  5. Appendix

Companies Mentioned

  • Gilead
  • Celgene

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xll3v3/histologic?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


            











    

        

        
Contact Data